Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Segmental Urethral Dosimetry and Urinary Toxicity in Patients With No Urinary Symptoms Before Permanent Prostate Brachytherapy

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [1];  [2];  [3]
  1. Department of Radiation Oncology, Vancouver Cancer Centre, Vancouver, BC (Canada)
  2. Radiation Oncology, Fraser Valley Cancer Centre, Surrey, BC (Canada)
  3. Surveillance and Outcomes Unit, British Columbia Cancer Agency, Vancouver, BC (Canada)

Purpose: To determine whether segmental urethral dosimetry is predictive for the degree of urinary morbidity after prostate brachytherapy in patients with no urinary symptoms before prostate brachytherapy. Methods and Materials: Between May 2000 and November 2005, 1,107 patients underwent iodine-125 monotherapy with urethral sparing techniques. A total of 166 patients fulfilled the selection criteria: baseline (International Prostate Symptom Score) IPSS {<=}5, no androgen deprivation therapy, and prostate ultrasound planning volumes (PUTV) <45 mL. The median follow-up was 44 months. Urinary morbidity was defined by maximum increase in IPSS, time to IPSS resolution, maximum Radiation Therapy Oncology Group (RTOG) score, time to RTOG resolution, and urinary retention. Surrogate deviated urethra was contoured and doses calculated at the base, mid-prostate, apex, and urogenital diaphragm. Univariate and multivariate analysis was used to evaluate urethral and prostate dosimetry, age, PUTV, and number of needles for their association with urinary morbidity. Results: Urethral dose was fairly constant in all urethra segments except prostate base, where the variation in does was large. On multivariate analysis, higher urethral base D50, V100, and larger PUTV were predictive for higher maximum increase in IPSS. Higher urethral base V100 and larger PUTV predicted for prolonged IPSS resolution. Higher urethral base D50 and larger needle number predicted for longer RTOG resolution. Higher urethral base V100 predicted for RTOG {>=}2 toxicity. Conclusions: Radiation dose to the urethral base, larger PUTV, and needle number, predicted for increased urinary toxicity after prostate brachytherapy. Correlation between urinary morbidity and urethral base dosimetry may reflect a large variation in urethral dose observed at the prostate base.

OSTI ID:
21124471
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 2 Vol. 72; ISSN IOBPD3; ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity
Journal Article · Fri Jul 15 00:00:00 EDT 2005 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20698603

Predictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive Patients
Journal Article · Sun Mar 15 00:00:00 EDT 2009 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21172660

Urinary Symptom Flare in 712 {sup 125}I Prostate Brachytherapy Patients: Long-Term Follow-Up
Journal Article · Sun Nov 01 00:00:00 EDT 2009 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21362196